Toda, Munetoyo
Ueno, Morio
Yamada, Jun
Hiraga, Asako
Asada, Kazuko
Hamuro, Junji
Sotozono, Chie
Kinoshita, Shigeru
Funding for this research was provided by:
Japan Agency for Medical Research and Development (19bm0404033h0002)
JSPS KAKENHI (JP26293376)
Article History
Received: 3 June 2022
Accepted: 17 October 2022
First Online: 27 October 2022
Competing interests
: Dr. Kinoshita has received grants and personal fees from Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd. CorneaGen and Kowa Co., Ltd. outside the submitted work. He has received grants from HOYA Corporation, Oncolys Biopharma Inc., Alcon Japan, Ltd. and Abbott Medical Optics, Inc. outside the submitted work. He has received personal fees from Novartis, Aurion Biotech outside the submitted work. In addition, He has a patent licensed and a patent pending. Dr. Sotozono has received grants and personal fees from Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Senju Pharmaceutical Co., Ltd. outside the submitted work. She has been received grants from Alcon Japan, Ltd., Nitto Medic Co., Ltd., SEED Co., Ltd., Nitten Pharmaceutical Co., Ltd., CorneaGen, Hirosaki LI and Kowa Company outside the submitted work. She has received personal fees from Toa Pharmaceutical Co.,Ltd. outside the submitted work. Dr. Ueno has received a grant from Alcon Japan, Ltd. He has received personal fees from CorneaGen, Aurion Biotech and Tomey Corporation outside the submitted work; In addition, He has a patent licensed and a patent pending. The other authors declare no potential conflict of interest.